GLP-1 Pipeline Update: November 2024 Quarterly view of the GLP-1 pipeline and anticipated indications Editorial team Maryam Tabatabai, PharmD Editor-In-Chief Vice President, Clinical Information Carole Kerzic, RPh Executive Editor Clinical Pharmacist, Drug Information Nicole Kjesbo, PharmD, BCPS Executive Editor Clinical Program Director, Pipeline Lisa Schweizer, PharmD, JD Director, Clinical Program Management Deputy Editor DISCLAIMER The drug pipeline is fluid
sodium-glucose cotransporter 2 inhibitors (SGLT2) in people with type 2 diabetes The 5-year survival probability for those with obesity and breast cancer using a GLP-1 was 97.4%, with the 10-year survival being 96%
Changes in the expression and activation state of proteins involved in cellmatrix interactions, including focal adhesion kinaserelated pathways, have been described
PlexusDx offers multiple delivery optionscompounded semaglutide injection ($189/mo), oral semaglutide ($289/mo), tirzepatide injection ($289/mo), or dual-compound GLP-Squared formulasallowing your provider to switch approaches if one causes excessive digestive distress